pi3k inhibitor acp 319

Drug Overview

The pi3k inhibitor acp 319 (also known as AMG-319) is an investigational medication designed to treat certain types of blood and lymphoid cancers. It is categorized as a Targeted Therapy and is often referred to as a “Smart Drug.” Unlike traditional chemotherapy, which can affect many different types of cells, ACP-319 is engineered to focus on specific signals inside cancerous immune cells.

This drug targets a very specific pathway that cancer cells use to grow, divide, and stay alive. By blocking this pathway, the medication aims to stop the cancer from spreading while potentially reducing the severe side effects often associated with broader treatments.

• Generic Name: ACP-319 (Investigational)
• US Brand Names: None (Not yet commercially available)
• Drug Class: Phosphoinositide 3-kinase (PI3K) Delta Inhibitor; Targeted Therapy
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Not FDA Approved (Currently in Phase 1 and Phase 2 clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how ACP-319 works, imagine that a cancer cell has a complex communication system. One of the main “telephone lines” in this system is the PI3K (Phosphoinositide 3-kinase) pathway. In many blood cancers, this line is constantly “ringing,” giving the cell a permanent instruction to grow and multiply.

At the molecular level, ACP-319 works through the following steps:

• Targeting the Delta Isoform: The PI3K enzyme comes in different forms (alpha, beta, gamma, and delta). The delta (δ) isoform is found primarily in white blood cells (leukocytes). ACP-319 specifically blocks this delta version.
• Interrupting the Signal: Once the drug binds to the PI3K-delta enzyme, it stops the production of a signaling molecule called PIP3.
• Stopping the Growth Engine: Without PIP3, a secondary protein called Akt cannot be activated. This breaks the PI3K/Akt/mTOR signaling pathway. This pathway is the primary “on switch” for cell survival.
• Cell Death: Once this switch is turned off, the cancer cell can no longer ignore the body’s natural signals to die. This leads to apoptosis (programmed cell death) of the malignant cells.

FDA-Approved Clinical Indications

As of early 2026, ACP-319 has not received full FDA approval. It is strictly available through clinical research studies for specific patient populations.

Oncological Uses (Investigational):

• Chronic Lymphocytic Leukemia (CLL): For patients whose cancer has returned after other treatments.
• Small Lymphocytic Lymphoma (SLL): A similar blood cancer involving the lymph nodes.
• Non-Hodgkin Lymphoma (NHL): Including follicular lymphoma and mantle cell lymphoma.

Non-oncological Uses:

• None.

Dosage and Administration Protocols

Because ACP-319 is in the clinical trial phase, the dosage is determined by the specific research study a patient joins. It is typically taken by mouth.

• 
  Dose Adjustments: If a patient develops signs of liver stress or severe diarrhea, the dose is typically paused or reduced. Currently, there is no standardized protocol for renal (kidney) or hepatic (liver) insufficiency outside of trial-specific guidelines.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 has focused on how well ACP-319 performs in patients who have run out of other treatment options.

• Overall Response Rate (ORR): In early-phase trials, ACP-319 has shown an ORR of approximately 35% to 50% in patients with relapsed blood cancers. This means their tumors shrank significantly.
• Disease Stability: Many patients achieved “Stable Disease,” where the cancer stopped growing for several months.
• Numerical Data: Recent research indicates that when combined with other Immunotherapies (like PD-1 inhibitors), the “Progression-Free Survival” (the time a patient lives without the cancer getting worse) can be extended, though exact numbers vary by the type of cancer.

Safety Profile and Side Effects

Like all PI3K delta inhibitors, ACP-319 has a specific safety profile that requires close monitoring by a medical team.

Black Box Warning

• None. (Investigational drugs do not receive Black Box Warnings until they are FDA-approved, though they carry warnings for potential liver and lung inflammation).

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired.
• Nausea and Diarrhea: Upset stomach is common.
• Cough: Usually mild, but requires monitoring.
• Skin Rash: Redness or itching.

Serious Adverse Events

• Hepatotoxicity: Damage to the liver, shown by high liver enzymes in blood tests.
• Colitis: Severe inflammation of the colon causing pain and diarrhea.
• Pneumonitis: Inflammation of the lungs (rare but serious).
• Infections: A lowered immune system can lead to serious lung infections (pneumonia).

Management Strategies

• Frequent Blood Tests: Used to catch liver issues early.
• Prophylactic Antibiotics: Sometimes given to prevent specific types of pneumonia.

Research Areas

In the fields of Immunotherapy and regenerative medicine, ACP-319 is a drug of high interest. Researchers are currently studying if blocking PI3K-delta can “reprogram” the environment around a tumor. By shutting down the signals that help cancer hide, the drug may help the body’s regenerating immune cells (like T-cells) see and attack the cancer more effectively. Ongoing trials are testing ACP-319 alongside Immune Checkpoint Inhibitors to see if this combination creates a more durable defense against cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Liver Function Panel: To check your baseline liver health.
• Complete Blood Count (CBC): To ensure your blood levels are safe for treatment.
• Infection Screening: Checking for viruses like Hepatitis B, C, and CMV.

Precautions During Treatment

• Symptom Tracking: Keep a daily log of bowel movements and report any sudden diarrhea immediately.
• Sun Protection: Some patients may become more sensitive to sunlight.

“Do’s and Don’ts” List

• DO report any new cough or shortness of breath to your oncology team immediately.
• DO take your medication at the same time every day to keep the levels steady.
• DON’T stop taking the medication without talking to your trial doctor, even if you feel better.
• DON’T take any new herbal supplements, as they can interfere with your liver’s ability to process the drug.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. ACP-319 is an experimental drug and is only available through clinical trials. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or participation in clinical research.